NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of Anika in connection with Anika's poor share performance, caused by the heavy losses it is incurring in its joint preservation segment, and its failure to maximize the value of Anika's viscosupplement portfolio.
The full text of the letter is in the attached PDF.
About Caligan Partners LP
Caligan Partners LP ("Caligan") is an SEC-registered investment advisor focused on active engagement with small and midcap companies within life sciences.
| Last Trade: | US$9.09 |
| Daily Volume: | 88,591 |
| Market Cap: | US$131.080M |
February 25, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
